Sargramostim: all 158 studies that test it

Page 2 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid TumorsCompletedNCT00091052Phase 1/2
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00089193Phase 2
• Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00089115Phase 3
• Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedNCT00089063Phase 2
• Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaWithdrawnNCT00085579Phase 2
• Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast CancerCompletedNCT00079157Phase 1
• Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
• Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's LymphomaCompletedNCT00071955Phase 2
• Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain TumorCompletedNCT00069940Phase 1
• Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
• Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaCompletedNCT00053157Not applicable
• Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00053131Phase 2
• Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast CancerCompletedNCT00052351Phase 2
• High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00050531Phase 3
• Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic MelanomaStatus unknownNCT00037037Phase 1
• Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the UterusTerminatedNCT00033644Phase 2
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue SarcomaTerminatedNCT00027911Phase 1
• Biological Therapy in Treating Women With Stage IV Breast CancerCompletedNCT00027807Phase 1
• Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate CancerCompletedNCT00020254Phase 2
• Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed NeuroblastomaCompletedNCT00017368Phase 2
• Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's LymphomaStatus unknownNCT00017290Phase 3
• Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the LungCompletedNCT00017121Phase 1
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With CancerTerminatedNCT00009958Phase 1
• Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck CancerCompletedNCT00008398Phase 3
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaCompletedNCT00006747Phase 2
• Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the LungCompletedNCT00006483Phase 2
• Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant MelanomaCompletedNCT00006243Not applicable
• Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00006240Phase 2
• Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple MyelomaTerminatedNCT00005987Phase 2
• Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung CancerCompletedNCT00005630Phase 1
• Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the LungCompletedNCT00005610Phase 2
• Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With NeuroblastomaCompletedNCT00005576Phase 1
• Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV CancerCompletedNCT00005023Phase 1
• Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal CancerCompletedNCT00004256Phase 2
• Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's LymphomaCompletedNCT00004198Phase 2
• Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00004197Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00004184Phase 1/2
• Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's LymphomaCompletedNCT00004162Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Prostate CancerCompletedNCT00004029Phase 1
• Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic SyndromeCompletedNCT00003961Phase 2
• Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant MelanomaCompletedNCT00003897Phase 1
• Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00003561Phase 2
• Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal InfectionCompletedNCT00003315Phase 3
• Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced TumorsCompletedNCT00003125Phase 2
• Surgery in Treating Children With NeuroblastomaCompletedNCT00003119Phase 3
• Combination Chemotherapy in Treating Children With NeuroblastomaCompletedNCT00003093Phase 3
• Topotecan Plus Sargramostim in Treating Patients With Advanced CancerCompletedNCT00002950Phase 1/2
• Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell TransplantationCompletedNCT00002787Phase 1
• Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00002778Phase 2
• Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal CancerWithdrawnNCT00002664Phase 2
• Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionCompletedNCT00002514Phase 3
• Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaCompletedNCT00002461Phase 2
• A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and LeukopeniaCompletedNCT00002009Phase 1
• An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and LeukopeniaCompletedNCT00002008Phase 1

← Sargramostim overview